Conflicts of interest: Nothing to report
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study
Article first published online: 31 JUL 2014
© 2014 Wiley Periodicals, Inc.
American Journal of Hematology
Volume 89, Issue 11, pages E200–E205, November 2014
How to Cite
Martinelli, I., De Stefano, V., Carobbio, A., Randi, M. L., Santarossa, C., Rambaldi, A., Finazzi, M. C., Cervantes, F., Arellano-Rodrigo, E., Rupoli, S., Canafoglia, L., Tieghi, A., Facchini, L., Betti, S., Vannucchi, A. M., Pieri, L., Cacciola, R., Cacciola, E., Cortelezzi, A., Iurlo, A., Pogliani, E. M., Elli, E. M., Spadea, A. and Barbui, T. (2014), Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study. Am. J. Hematol., 89: E200–E205. doi: 10.1002/ajh.23809
- Issue published online: 16 OCT 2014
- Article first published online: 31 JUL 2014
- Accepted manuscript online: 19 JUL 2014 02:43AM EST
- Manuscript Received: 16 JUL 2014
- Manuscript Accepted: 16 JUL 2014
- Associazione Italiana per la Ricerca sul Cancro -“AIRC 5 per Mille”- to AGIMM, “AIRC-Gruppo Italiano Malattie Mieloproliferative” . Grant Number: #1005
To investigate the characteristics and clinical course of cerebral vein thrombosis (CVT) in patients with myeloproliferative neoplasms (MPN) we compared 48 patients with MPN and CVT (group MPN-CVT) to 87 with MPN and other venous thrombosis (group MPN-VT) and 178 with MPN and no thrombosis (group MPN-NoT) matched by sex, age at diagnosis of MPN (±5 years) and type of MPN. The study population was identified among 5,500 patients with MPN, from January 1982 to June 2013. Thrombophilia abnormalities were significantly more prevalent in the MPN-CVT and MPN-VT than in MPN-NoT group (P = 0.015), as well as the JAK2 V617F mutation in patients with essential thrombocythemia (P = 0.059). Compared to MPN-VT, MPN-CVT patients had a higher rate of recurrent thrombosis (42% vs. 25%, P = 0.049) despite a shorter median follow-up period (6.1 vs. 10.3 years, P = 0.019), a higher long-term antithrombotic (94% vs. 84%, P = 0.099) and a similar cytoreductive treatment (79% vs. 70%, P = 0.311). The incidence of recurrent thrombosis was double in MPN-CVT than in MPN-VT group (8.8% and 4.2% patient-years, P = 0.022), and CVT and unprovoked event were the only predictive variables in a multivariate model including also sex, blood count, thrombophilia, cytoreductive, and antithrombotic treatment (HR 1.97, 95%CI 1.05–3.72 and 2.09, 1.09–4.00, respectively). Am. J. Hematol. 89:E200–E205, 2014. © 2014 Wiley Periodicals, Inc.